New heart valve device aims to fix tricuspid leak without open surgery

NCT ID NCT07687485

First seen Jul 07, 2026 · Last updated Jul 23, 2026 · Updated 3 times

Summary

This study tests a new device called the Laplace Transcatheter Tricuspid Valve Replacement (TTVR) System for people with severe tricuspid regurgitation, a condition where the heart's tricuspid valve leaks blood backward. The device is placed through a catheter, avoiding open-heart surgery. The trial includes up to 700 participants with severe symptoms despite medical therapy, and compares the Laplace system to another approved device. The goal is to see if the new device is safe and improves quality of life and heart function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Laplace Transcatheter Tricuspid Valve Replacement System
What this could lead to
If successful, this could offer a less invasive treatment option for people with severe tricuspid regurgitation, potentially reducing symptoms and hospitalizations.
What could go wrong
This is an early study of a new device, so its safety and effectiveness are not yet proven. Risks include complications from the procedure, device failure, or no improvement in symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASES (CVD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.